Corcept Therapeutics
CORT
222 hedge funds and large institutions have $1.22B invested in Corcept Therapeutics in 2018 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 68 reducing their positions, and 26 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
62% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 26
16% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 68
7% more funds holding
Funds holding: 207 → 222 (+15)
1.58% more ownership
Funds ownership: 77.22% → 78.8% (+1.6%)
3% less capital invested
Capital invested by funds: $1.26B → $1.22B (-$41M)
38% less call options, than puts
Call options by funds: $6.78M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$15.5M |
| 2 |
Millennium Management
New York
|
+$8.1M |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$6.04M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$6.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$16.1M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.87M |
| 3 |
Capital Fund Management (CFM)
Paris,
France
|
-$7.58M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.41M |
| 5 |
Morgan Stanley
New York
|
-$4.87M |
CORT Hedge Fund Activity: Q4 2018 in Review
222 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2018, worth a combined $1.22B — down 3.3% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new CORT positions and 26 closed out — a net gain of 16 holders — while 79 added to existing stakes and 68 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $15.5M. The largest seller was Acadian Asset Management, cutting an estimated $16.1M.
- 222 institutional investors held Corcept Therapeutics (CORT) as of Q4 2018, up from 207 in Q3 2018.
- Funds reported $1.22B of Corcept Therapeutics stock for Q4 2018, down 3.3% quarter-over-quarter.
- 42 funds opened new Corcept Therapeutics positions in Q4 2018 and 26 closed out, a net change of +16 holders.
- The largest Corcept Therapeutics buyer in Q4 2018 was Consonance Capital Management, an estimated $15.5M added.
- The largest Corcept Therapeutics seller in Q4 2018 was Acadian Asset Management, an estimated $16.1M sold.
Based on aggregated 13F filings for Q4 2018.